Výsledky vyhledávání - "Erin Willert"

Abstract P1-18-35: MT-5111, a novel HER2 targeting engineered toxin body, under clinical development to overcome mechanisms of resistance to existing HER2 targeted therapies

Autor: Eric T Williams, Roger J. Waltzman, Jack P. Higgins, Asis K. Sarkar, Aimee Iberg, Erin Willert

Publikováno v: Cancer Research. 80:P1-18

Engineered toxin bodies (ETBs) are differentiated, targeted therapeutics comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLTA) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of actio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a688f92e5ff9ac875978716924133b4b
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-35

Zobrazit plný text záznamu

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Autor: John Newcomb, Wenrou Zheng, Wassilis S. C. Bruins, Niels W.C.J. van de Donk, Erin Willert, Tuna Mutis, Jack P. Higgins, Sonja Zweegman, Ajeeta B Dash

Publikováno v: Blood. 136:11-12

Monoclonal antibodies (daratumumab, anti-CD38; elotuzumab, anti-SLAMF7) and BCMA-targeting T-cell redirecting therapies are highly effective in a large proportion of multiple myeloma (MM) patients. Nonetheless, age, prior (chemo)therapy, and the tumo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35962402889839bba74a70ddd4c831af
https://doi.org/10.1182/blood-2020-136928

Zobrazit plný text záznamu

Abstract 2060: Combination of CD20 targeted engineered toxin body, MT-3724, with chemotherapy or IMiDs for the treatment of non Hodgkin's lymphoma

Autor: Caleigh Howard, Erin Willert, Jack P. Higgins, Aimee Iberg

Publikováno v: Cancer Research. 79:2060-2060

MT-3724 is a novel recombinant fusion protein consisting of a CD20 binding variable fragment (scFv) fused to Shiga-like toxin-I A1 (SLTA) ribosome inactivating protein. Engineered Toxin Bodies (ETBs) are unique as they can induce internalization afte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e288a999b585fa74945cfe8cedd00f18
https://doi.org/10.1158/1538-7445.am2019-2060

Zobrazit plný text záznamu

Abstract 521: CD45 targeted engineered toxin bodies deplete hematopoietic and malignant cells

Autor: Garrett L. Robinson, Aimee Iberg, Melissa M. Singh, Joseph D. Dekker, Hilario J. Ramos, Jay Zhao, Sara LeMar, Erin Willert

Publikováno v: Cancer Research. 80:521-521

CD45 is highly expressed on the cell surface of all nucleated hematopoietic cells, including malignant cells of B, T and myeloid lineage. CD45, a receptor tyrosine phosphatase that has important roles in antigen receptor signaling, has multiple isofo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a7bd4e6d818690a927193b29694d2ce
https://doi.org/10.1158/1538-7445.am2020-521

Zobrazit plný text záznamu

Abstract 3366: In vivo efficacy of a PD-L1 targeted, antigen seeding engineered toxin body

Autor: Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Aimee Iberg, Asis K. Sarkar, Banmeet Anand, Brigitte Brieschke, Melissa M. Singh, Jack P. Higgins, Jay Zhao, Erin Willert

Publikováno v: Cancer Research. 80:3366-3366

Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLTA) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-route through intr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97d1969a145eabf16102804111c31a3e
https://doi.org/10.1158/1538-7445.am2020-3366

Zobrazit plný text záznamu

Abstract 2278: CTLA-4 targeted engineered toxin bodies designed to deplete regulatory T cells (Tregs)

Autor: Aimee Iberg, Joseph D. Dekker, Garrett L. Robinson, Edith Acquaye-Seedah, Erin Willert, Hilario J. Ramos, Lilia A. Rabia, Jay Zhao

Publikováno v: Cancer Research. 80:2278-2278

Tumor resident regulatory T cells (Tregs) are important mediators of an immunosuppressive tumor microenvironment (TME) promoting tumor immune evasion. The presence of Tregs, and a higher ratio of Tregs to effector T cells in the TME, are associated w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4ac11ff4307e6c0ec0a603d5357a941
https://doi.org/10.1158/1538-7445.am2020-2278

Zobrazit plný text záznamu

Abstract 539: Novel engineered toxin bodies targeting SLAMF7 (CS1)

Autor: Hilario J. Ramos, Erin Willert, Jay Zhao, Caleigh Howard, Garrett L. Cornelison, Garrett L. Robinson, Aimee Iberg

Publikováno v: Cancer Research. 80:539-539

Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable of forcing internal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dac11b98460e0c4cd68c3f5bb7a65f4b
https://doi.org/10.1158/1538-7445.am2020-539

Zobrazit plný text záznamu

PD-L1 targeted engineered toxin body provides direct cytotoxicity and T-cell mediated tumor targeting

Autor: Roger J. Waltzman, Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Brigitte Brieschke, Garrett L. Cornelison, Aimee T. Iberg, Asis K. Sarkar, Erin Willert, Jay Zhao

Publikováno v: Journal of Clinical Oncology. 38:12-12

12 Background: Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-ro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b661295508d489a702c96aa893aa08e8
https://doi.org/10.1200/jco.2020.38.5_suppl.12

Zobrazit plný text záznamu

MT-5111: A novel HER2 targeting engineered toxin body in clinical development

Autor: Jack T. Higgins, Roger J. Waltzman, Aimee T. Iberg, Asis K. Sarkar, Eric T Williams, Erin Willert

Publikováno v: Journal of Clinical Oncology. 38:433-433

433 Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered Shiga-like Toxin A subunit genetically fused to antibody-like binding domains. MT-5111 is a de-immunized ETB targeting HER2 for solid tumors. MT-5111 works thr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0aa977feff26c733bdd5663bacfd8e2
https://doi.org/10.1200/jco.2020.38.4_suppl.433

Zobrazit plný text záznamu

Abstract P4-15-17: A novel targeted engineered toxin body for treatment of HER2 positive breast cancer

Autor: Garrett L. Robinson, Erin Willert, Jack P. Higgins, Sangeetha Rajagopalan, Brigitte Brieschke, Jennifer Erdman, William Null

Publikováno v: Cancer Research. 75:P4-15

The HER2 receptor is overexpressed in 20-30% of breast cancers. HER2 overexpression in breast cancer has been successfully targeted by both antibody and antibody-drug conjugate (ADC) approaches. The recently approved trastuzumab-emtansine (T-DM1, Kad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df97489205e11ca97f35824cc574057c
https://doi.org/10.1158/1538-7445.sabcs14-p4-15-17

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání